Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Hepatol. Nov 27, 2013; 5(11): 635-641
Published online Nov 27, 2013. doi: 10.4254/wjh.v5.i11.635
Table 1 Patient baseline and demographic characteristics, and treatment response in the present study
TotalPNALTAbnormal ALTP value
Number of patients278100178
Age (yr)55.6 ± 11.456.2 ± 10.955.3 ± 11.60.526
Gender (male/female)136/14231/69105/73< 0.0001
AST (IU/L)56.6 ± 44.729.8 ± 12.171.3 ± 49.1< 0.0001
ALT (IU/L)70.5 ± 64.327.6 ± 7.294.6 ± 69.4< 0.0001
γ-GT (IU/L)50.7 ± 57.326.2 ± 22.164.1 ± 65.7< 0.0001
WBC (/mm3)5190 ± 15005060 ± 14905260 ± 15100.28
Hemoglobin (g/dL)14.4 ± 7.113.5 ± 1.215.0 ± 8.90.094
Platelets (× 104/mm3)17.1 ± 5.617.7 ± 5.916.8 ± 5.50.20
Previous treatment (-/+)211/6775/25136/420.90
IL-28B SNP(Maj/Min)189/8970/30119/590.68
VR/Null response203/6584/16129/490.042
RVR (+/-)32/20012/7020/1300.93
EVR (+/-)116/11846/3670/820.18
SVR (+/-)143/13556/4487/910.30
Table 2 Baseline characteristics of hepatitis C virus-infected patients, according to interleukin 28B single-nucleotide polymorphism rs8099917
IL-28B rs8099917PNALT group (n = 100)
Abnormal ALT group (n = 178)
MajorMinorP valueMajorMinorP value
Number of patients703011959
Age (yr)57.7 ± 10.852.6 ± 10.50.03155.3 ± 11.355.4 ± 12.30.95
Gender (male/female)21/4910/200.9268/5137/220.58
AST (IU/L)29.3 ± 13.130.9 ± 9.70.5869.4 ± 51.475.4 ± 44.10.47
ALT (IU/L)26.8 ± 7.229.5 ± 7.00.08692.1 ± 70.499.5 ± 67.80.5
γ-GT (IU/L)21.0 ± 11.538.4 ± 33.80.0006954.0 ± 41.385.1 ± 95.70.0056
WBC (/mm3)5130 ± 14404900 ± 16400.525280 ± 1,6805230 ± 10700.84
Hemoglobin (g/dL)13.3 ± 1.013.9 ± 1.50.0215.3 ± 10.814.4 ± 1.10.52
Platelets (× 104/mm3)17.2 ± 5.718.8 ± 6.30.2117.0 ± 5.316.4 ± 5.80.49
Previous treatment (-/+)54/1621/90.6193/2643/160.55
VR/Null response63/721/90.02798/2131/230.000059
RVR (+/-)9/503/200.9217/843/460.12
EVR (+/-)38/218/150.02959/4411/380.00011
SVR (+/-)44/2612/180.05867/5220/390.0079
Table 3 Hepatitis C virus genotype 1-infected patient with persistent normal alanine aminotransferase and interleukin 28B single-nucleotide polymorphism
IL-28B rs8099917MajorMinorP valueSVRNon-SVRP value
Number of patients54183636
Age (yr)58.4 ± 10.954.6 ± 11.00.2056.6 ± 13.458.4 ± 8.00.49
Gender (male/female)17/377/110.7714/2210/260.45
AST (IU/L)30.3 ± 14.534.5 ± 10.30.2913.2 ± 1.132.0 ± 6.3< 0.00010
ALT (IU/L)27.5 ± 6.731.7 ± 5.60.01927.3 ± 7.429.8 ± 5.70.11
γ-GT (IU/L)21.7 ± 11.947.3 ± 39.30.0002419.7 ± 10.639.2 ± 32.70.0011
WBC (/mm3)5020 ± 14104570 ± 13500.275000 ± 13504780 ± 14700.51
Hemoglobin (g/dL)13.3 ± 0.913.7 ± 1.50.1713.2 ± 1.113.5 ± 1.10.25
Platelets (× 104/mm3)16.6 ± 6.017.0 ± 5.60.8017.1 ± 6.016.2 ± 5.80.51
Previous Treatment (-/+)42/1212/60.5229/725/110.41
VR/Null response46/89/90.006436/019/17< 0.00010
RVR (+/-)6/380/160.286/270/270.057
EVR (+/-)25/191/150.001323/103/24< 0.00010
SVR (+/-)34/202/160.00040
IL-28B SNP rs8099917
(Maj/Min)34/220/160.00040
Table 4 Factors associated with sustained virologic response among hepatitis C virus genotype 1-infected patients with persistent normal alanine aminotransferase by multivariate analysis
FactorCategoryOdds ratio95%CIP value
IL-28B rs8099917Major/Minor7.111.305-38.7990.023
EVR(+/-)13.283.242-54.3990.0003